Brain insulin may hold key to schizophrenia's cognitive fog

NCT ID NCT05748990

Recruiting now Knowledge-focused Sponsor: Centre for Addiction and Mental Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates whether abnormal insulin action in the brain contributes to cognitive and metabolic problems in schizophrenia. Twenty participants (some with schizophrenia, some healthy) will receive either intranasal insulin or a placebo before a PET scan that measures brain glucose uptake. The goal is to see if brain insulin resistance is linked to thinking and memory challenges in schizophrenia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intranasal insulin (Humalog)
What this could lead to: If successful, this could reveal a link between brain insulin resistance and cognitive problems in schizophrenia, pointing toward new treatment targets.
What could go wrong: This is a very small, early-stage study (20 people) that only measures brain activity, not clinical outcomes. It may not lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SCHIZOPHRENIA

Contacts and locations

Locations

Centre for Addiction and Mental Health
RECRUITING

Toronto, Ontario, M6J1H3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.